View Older Stories View More Recent Stories

Mar 1, 2023 08:00AM Recursion to Participate in Upcoming Investor Conferences
Mar 1, 2023 08:00AM Recursion to Participate in Upcoming Investor Conferences
Feb 27, 2023 04:30PM Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Feb 1, 2023 08:01AM Recursion to Participate in Upcoming Investor Conference
Jan 26, 2023 08:30AM Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day
Dec 20, 2022 07:55AM Recursion to Participate in Upcoming Investor Conferences
Nov 8, 2022 04:30PM Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results
Nov 2, 2022 07:59AM Recursion to Participate in Upcoming Investor Conferences
Oct 25, 2022 08:05AM Recursion Pharmaceuticals (RXRX) Announces $150M Private Placement at $9.80/sh
Oct 25, 2022 08:00AM Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB
Sep 13, 2022 07:59AM Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022
Sep 1, 2022 07:55AM Recursion to Participate in Upcoming Investor Conferences
Aug 18, 2022 07:55AM Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum
Aug 9, 2022 04:15PM Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results
Aug 2, 2022 07:55AM Recursion to Participate in Upcoming Investor Conference
Jul 21, 2022 07:55AM Recursion Pharmaceuticals (RXRX) Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
Jul 21, 2022 07:55AM Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
Jun 20, 2022 07:55AM Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference
Jun 2, 2022 07:55AM Recursion to Participate in Upcoming Investor Conferences
May 10, 2022 04:29PM Recursion Provides Business Updates and Reports First Quarter 2022 Financial Results
May 2, 2022 07:55AM Recursion to Participate in Upcoming Investor Conference
Apr 11, 2022 07:55AM Recursion Pharmaceuticals (RXRX) Granted FDA Fast Track Designation for REC-4881
Apr 11, 2022 07:55AM Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
Mar 31, 2022 07:55AM Recursion to Participate in Upcoming Investor Conferences
Mar 30, 2022 07:55AM Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital
Mar 24, 2022 07:55AM Recursion Publishes First Environmental, Social and Governance (ESG) Report
Mar 23, 2022 07:55AM Recursion Pharmaceuticals (RXRX) Reports Q4 Results, Provides Business Updates
Mar 23, 2022 07:55AM Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Mar 18, 2022 07:55AM Recursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation
Mar 3, 2022 07:55AM Recursion Provides Updated Guidance on Clinical Trial Starts
Mar 2, 2022 08:47AM Recursion to Participate in Upcoming Investor Conferences
Feb 8, 2022 07:55AM Recursion to Participate in Upcoming Investor Conferences
Dec 7, 2021 07:55AM Recursion Pharmaceuticals (RXRX) Announces Collaboration with Roche and Genentech in Neuroscience and Oncology
Dec 7, 2021 07:55AM Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Method
Dec 6, 2021 07:56AM Recursion Pharmaceuticals (RXRX) Expands Fibrosis Collaboration with Bayer to Include Inferential Search Capabilities
Dec 6, 2021 07:55AM Recursion and Bayer Expand Fibrosis Collaboration to Include Inferential Search Capabilities
Nov 30, 2021 07:55AM Recursion Enhances its Leadership Team and Deepens Focus on Neuroscience with Three Senior Appointments
Nov 10, 2021 07:55AM Recursion Provides Business Updates and Reports Third Quarter 2021 Financials
Oct 7, 2021 07:56AM Recursion Pharmaceuticals (RXRX) Granted FDA Fast Track Designation for REC-2282 for Treatment of NF2-Mutated Meningiomas
Oct 7, 2021 07:55AM Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas
Sep 29, 2021 08:55AM Recursion Pharmaceuticals (RXRX) Granted Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
Sep 29, 2021 08:54AM Recursion is Granted Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
Aug 13, 2021 07:55AM Recursion Reports Second Quarter 2021 Financials and Provides Business Updates
Jul 13, 2021 07:55AM Recursion Announces Therapeutics Advisory Board, Chaired by Joseph Miletich, MD, PhD
Jul 12, 2021 04:41PM Recursion Opens Child Care Center to Support Employees
Jul 1, 2021 08:54AM Recursion Signs Lease With Vestar for an Additional 100,000 sf of Space at the Gateway in Downtown Salt Lake City
Jun 23, 2021 08:54AM Recursion Pharmaceuticals (RXRX) Announces Multi-Year Collaboration with Mila for Tech-Enabled Drug Discovery
Jun 23, 2021 08:53AM Recursion Announces Multi-Year Collaboration with Mila for Tech-Enabled Drug Discovery
Jun 15, 2021 08:54AM Recursion Announces its First Major Multidisciplinary Expansion, in Toronto, to Further Tech-Enabled Drug Discovery
View More Recent Stories View Older Stories